Clinical Trial Search

Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…

Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants

Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants

Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale

Primary: Participants Enrolled — 36 Participants

Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants

Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person

Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants

Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…

Primary: Instrumental Activities of Daily Living and Activities of Daily Living (I/ADL) Score — 3.40; 3.05; 3.50; 3.40 I/ADL Score — p=0.77

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants

Primary: SARS-CoV-2 Infection — 4; 2 Participants

Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…

Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants

Primary: 30 Candidate Ag Test Self-collections — 53; 0 Participants

Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561

Primary: Number of Participants With COVID-19 Antibodies — 8; 284 Participants — p=>0.18

Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants

Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant

Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants

Primary: Positive Percent Agreement — 53; 2 Participants

Primary: Sambucol Reduces the Severity of Symptoms by at Least 30% by Day 10 in People Who Are Symptomatic With the SARS-CoV-2 (COVID-19) Virus, Compared to Placebo. — 84.3; 86.5…

Primary: Positive Percent Agreement — 52 percent of nasal swabs

Primary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants

Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants

Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements

Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…

Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…

Primary: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination — 10; 12; 10; 2 Participants

Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free